Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Operating Leases (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 3 years of Operating Leases data on record, last reported at $22.0 million in Q4 2025.

  • For Q4 2025, Operating Leases fell 31.25% year-over-year to $22.0 million; the TTM value through Dec 2025 reached $22.0 million, down 31.25%, while the annual FY2025 figure was $22.0 million, 31.25% down from the prior year.
  • Operating Leases reached $22.0 million in Q4 2025 per INDV's latest filing, down from $24.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $34.0 million in Q4 2023 and bottomed at $22.0 million in Q4 2025.
  • Average Operating Leases over 3 years is $28.5 million, with a median of $29.5 million recorded in 2025.
  • Peak YoY movement for Operating Leases: dropped 5.88% in 2024, then crashed 31.25% in 2025.
  • A 3-year view of Operating Leases shows it stood at $34.0 million in 2023, then dropped by 5.88% to $32.0 million in 2024, then plummeted by 31.25% to $22.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $22.0 million in Q4 2025, $24.0 million in Q3 2025, and $29.0 million in Q2 2025.